EMA postpones data disclosure policy, but no new implementation date
This article was originally published in Scrip
The European Medicines Agency has confirmed that the implementation of its new policy on clinical trial data disclosure will be delayed well beyond the original 1 January 2014 implementation date because of the need to clarify aspects such as the publication of clinical study reports and the de-identification of patient data.
You may also be interested in...
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.
France is exploring the use of hydroxychloroquine and lopinavir/ritonavir in COVID-19, but only in hospitalized patients and in clinical trials, and has banned all exports of the products to avoid possible shortages.
Efforts are under way in the UK on many fronts to develop new treatments and vaccines for coronavirus infection, including researching new uses of existing products and clinical trials of new vaccines.